Recent Updates
Recently added Catalysts

BON-106

Phase 1

Solid Tumor | Small molecule | Oncology |BeOne Medicines Ltd.|Trials Updated: Oct 26, 2026

BON-106 development status

Highest phase Phase 1
Registered trials 1 across 1 sponsor since Oct 2026

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

CONTROLLED
Total Trials1
Total Enrollment96

FDA Designations

No designations recorded

BON-106 clinical trials

BON-106 · 1 trial · 3 indications

Phase 1 1
NCT07893535An Investigational Study of BON-106 in Adults With Advanced or Metastatic Solid TumorsSolid Tumor
NOT YET_RECRUITING96 Analytics
PHASE1NOT YET_RECRUITING
An Investigational Study of BON-106 in Adults With Advanced or Metastatic Solid Tumors
Solid Tumor
NCT0789353596
Unlock trial analytics

Study Endpoints

Primary Endpoints

Dose Escalation Phase: Number of Participants with Dose-limiting Toxicities (DLTs)
Up to approximately 1 month
Dose Escalation Phase: Number of Participants with Treatment-emergent Adverse Events (TEAEs), Treatment-related Adverse Events (TRAEs), and Serious Adverse Events (SAEs)
From first dose of study drug until 30 days after last dose, up to approximately 24 months.
Dose Expansion Phase: Objective Response Rate (ORR)
Up to approximately 24 months

ORR is defined as the percentage of participants with a best overall response (BOR) of a complete response (CR) or partial response (PR) with confirmation per the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria.

Secondary Endpoints

Dose Escalation Phase: Objective Response Rate (ORR)
Up to approximately 24 months
Duration of Response (DOR)
Up to approximately 24 months
Disease Control Rate (DCR) at Week 12 and Week 24
Week 12 and Week 24
Unlock Study Endpoints

Study Design & Arms

AllocationNON_RANDOMIZED
MaskingNONE
ModelSEQUENTIAL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Phase 1a Dose EscalationEXPERIMENTALSequential cohorts of increasing dose levels of BON-106 will be evaluated.
Phase 1b Dose ExpansionEXPERIMENTALParticipants with selected advanced solid tumors will receive BON-106 at the selected dose(s).

Interventions

NameTypeDescription
BON-106DRUGAdministered by intravenous infusion
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo

Inclusion Criteria: * Patients must be ≥ 18 years of age and must sign the ICF and be capable of giving written informed consent * Patients must have either experienced disease recurrence or progression following standard systemic therapy, been intolerant of or ineligible for standard therapy, have...

Unlock Eligibility Criteria

Competitive Landscape -Other Solid Tumors 10 trials (matched to "Solid Tumor")

CompanyTickerTrialsLead PhaseDrugs
Merck & Co., Inc.MRK3PHASE2Pembrolizumab, Gardasil 9
Incyte CorporationINCY1PHASE2Retifanlimab
Novartis AG Sponsored ADRNVS1PHASE1KFA115
Iovance Biotherapeutics IncIOVA2PHASE2Aldesleukin
AstraZeneca PLCAZN1 - Trastuzumab deruxtecan
Unlock Competitive Intelligence

Recent Changes (Last 90 Days)

LOWOct 26, 2026NCT07893535NEW_TRIAL: changed
LOWOct 26, 2026NCT07893535NEW_TRIAL: changed

Explore more on BiopharmaWatch

BeOne Medicines Ltd. (ONC)Pipeline, catalysts, financials, insiders and newsBiotech disease mapWho is developing what in each indication, and how crowded it isFDA calendarUpcoming PDUFA dates, AdComs and approval oddsPDUFA calendarEvery scheduled FDA decision date, month by monthHistorical FDA calendarPast decisions and how the stock moved on eachCatalyst SyncUpcoming readouts and decisions, screened by runway and phaseBiotech stock screenerFilter by clinical phase, cash runway and market capDrugs A to ZEvery drug page starting with BCompanies A to ZEvery biotech and pharma company we track